Charles Schwab
RKDA icon

Charles Schwab’s Arcadia Biosciences RKDA Stock Holding History

Charles Schwab’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-14
Closed -$31K – 3128
2016
Q1 		$31K Hold
14
– – ﹤0.01% 3039
2015
Q4 		$34K Hold
14
– – ﹤0.01% 3079
2015
Q3 		$34K Hold
14
– – ﹤0.01% 3075
2015
Q2 		$71K Buy
+14
New +$87.1K ﹤0.01% 3063

Other funds holding RKDA

WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
LRPA
L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Charles Schwab's RKDA Position: Q2 2016 in Review

Charles Schwab sold out of Arcadia Biosciences (RKDA) in Q2 2016, closing a stake of 14 shares — an estimated $31K sold.

Charles Schwab first reported a position in RKDA in Q2 2015 and held it in 4 quarters. The position peaked at $71K in Q2 2015. 20 funds tracked by Wall St. Rank hold RKDA as of Q2 2016.

  • Charles Schwab reported no remaining Arcadia Biosciences position as of Q2 2016 after selling out during the quarter.
  • Charles Schwab sold 14 Arcadia Biosciences shares in Q2 2016, an estimated $31K.
  • Charles Schwab first reported a position in Arcadia Biosciences in Q2 2015 and held it in 4 quarters.
  • Charles Schwab's Arcadia Biosciences position peaked at $71K in Q2 2015.
  • 20 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2016.

Based on Charles Schwab's 13F filing for Q2 2016, filed 15 Aug 2016.